Alicia Castañeda Heredia
Investigador
Research group
Professional network profiles
Last Publications
- Kuhlen M, Roganivic J, Naviglio S, Baecklund F, Bello R, Ben-Ami T, Bergamaschi L, Bilic E, Bien E, Brito MJ, Castañeda-Heredia A, Cesen Mazic M, Dos Reis Farinha NJ, Jovanovska A, de Krijger R, Debora de Pasquale M, Elisei R, Grau Bolado G, Guillén G, Haissaguerre M, Hartl D, Huerta-Aragonés J, Krawczyk MA, Lamartina L, Leite F, Leite V, López Almaraz R, Manevska N, Mansuy L, Miele E, Naderi EH, Nordmann Winther T, Petit IO, Özön ZA, Podda MG, Pourtsidis A, Reguerre Y, Sandström M, Schneider DT, Ekinci S, Suput Omladic J, Sztangierska B, Verite C, Waespe N, Wong KH, Yalcin B, Abele M, Bisogno G, Orbach D, Brecht IB, Virgone C and Redlich A Who leads, who treats, what dose? European paediatric differentiated thyroid carcinoma practice-an European Cooperative Study Group for Paediatric Rare Tumours survey. EUROPEAN JOURNAL OF ENDOCRINOLOGY . 194(6): 756-768.
- Santa-María López V, Felip-Badia A, Marina Caballero Bellón, Sanchez-Sierra N, Castañeda-Heredia A, Garraus-Oneca M, Gorostegui M, Simão-Rafael M, Muñoz JP, Pérez-Somarriba M, Mañe S, Planells MC, Pérez-Jaume S and Mora J Prognostic Impact of Treatment Modalities, Including Targeted Compartmental Radio-Immunotherapy, in a Cohort of Neuroblastoma Patients With CNS Metastases at Relapse PEDIATRIC BLOOD & CANCER . 73(4): .
- Ortega-Bertran S, Fernández-Rodríguez J, Magallón-Lorenz M, Creus-Bachiller E, Uriarte-Arrazola I, Mazuelas H, Garraus-Oneca M, Carrió M, Gel B, Rovira-Zurriaga C, Alvarez M, Villanueva A, Castañeda-Heredia A, Salvador-Hernandez H, Serra E and Lázaro C Personalized medicine strategy for MPNSTs: using precision oncology on PDOX models to inform tumor boards Journal of Translational Medicine . 24(1): .
Projects
- Project name:
- Disrupción de enhancers: la nueva generación de terapia epigenética en el sarcoma de Ewing
- Leader
- Jaume Mora Graupera, Sara Sánchez Molina
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI24/00804
- Starting - finishing date:
- 2025 - 2027
- Project name:
- ICF (Exploratory study on the provision of care for Adolescent and Young Adult (AYA) cancer patients in the Union)
- Leader
- Andrés Morales La Madrid
- Funding entities:
- European Commission
- Code
- 330301961
- Starting - finishing date:
- 2025 - 2026
- Project name:
- SEHOP-PENCIL study - Personalised mEdiciNe for Cancer in chILdren in Spain
- Leader
- Cinzia Emilia Lavarino
- Funding entities:
- Lavarino, Cinzia Emilia, Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD
- Code
- PMP21/00075
- Starting - finishing date:
- 2022 - 2026
News
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.
